Skip to main
XGN

Exagen Inc (XGN) Stock Forecast & Price Target

Exagen Inc (XGN) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Exagen is expected to have a strong year ahead with the launch of new biomarkers, improved reimbursement and billing initiatives, and sustainable growth in test ASPs. This, coupled with the company's recent positive revenue and volume performance, makes us optimistic about its future growth potential. Furthermore, Exagen's recent expansion of its sales force and plans to launch one new product per year position the company for continued success in the market.

Bears say

Exagen is a medical technology company focused on offering proprietary diagnostic tests to a targeted population of rheumatologists, with a strategy to become a value-added partner in the diagnosis, monitoring, and treatment of autoimmune diseases. Despite a large US addressable market and significant unmet need, Exagen faces the challenge of a small target physician population and potential competition in the future. Its financial success will depend on the successful development of new tests and establishing partnerships with its physician customers.

Exagen Inc (XGN) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exagen Inc (XGN) Forecast

Analysts have given Exagen Inc (XGN) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Exagen Inc (XGN) has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exagen Inc (XGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.